Sildenafil — the compound most people know as Viagra — was approved by the FDA in June 2005 under the brand name Revatio to treat pulmonary arterial hypertension, a dangerous condition in which blood pressure in the lungs climbs high enough to strain and eventually fail the right side of the heart. A second erectile dysfunction drug, tadalafil, followed in May 2009 under the brand name Adcirca. Both belong to a class called PDE5 inhibitors, and their crossover from the bedroom to the cardiopulmonary ward represents one of modern medicine’s more striking examples of drug repurposing — one that matters to brain health more than most people realize. For the estimated 192,000 people living with pulmonary arterial hypertension worldwide as of 2021, these medications have meaningfully improved survival.
Before targeted therapies existed, outcomes were grim. Today, five-year survival rates have climbed to roughly 68 percent, according to the REVEAL Registry. That progress is significant, but it also raises questions that families dealing with cognitive decline should understand: how reduced oxygen delivery from PAH affects the brain, what these drugs do and do not protect against, and why the intersection of cardiovascular and neurological health deserves closer attention. This article walks through the science, the practical differences between the two approved drugs, and what caregivers and patients should keep in mind.
Table of Contents
- How Did Erectile Dysfunction Drugs Get Approved for Pulmonary Hypertension?
- Why Pulmonary Arterial Hypertension Matters for Brain Health
- How Revatio and Adcirca Differ in Practice
- Understanding PAH Diagnosis and Who Is Most at Risk
- Survival Rates and the Limits of Treatment
- Drug Interactions and Safety Concerns for Older Adults
- Research Directions and the Brain-Lung Connection
- Conclusion
- Frequently Asked Questions
How Did Erectile Dysfunction Drugs Get Approved for Pulmonary Hypertension?
The story begins with an accidental discovery. Sildenafil was originally developed by Pfizer as a cardiovascular drug for angina. During clinical trials in the 1990s, researchers noticed it had a pronounced effect on erections — and a blockbuster was born when Viagra received FDA approval on March 27, 1998. But the original cardiovascular mechanism never stopped being relevant. Sildenafil works by inhibiting phosphodiesterase type 5, an enzyme that breaks down a molecule called cyclic GMP. When PDE5 is blocked, blood vessels relax. In the lungs, that relaxation lowers pulmonary arterial pressure.
In simpler terms, the same chemical pathway that increases blood flow in one part of the body can ease dangerous pressure in another. The FDA approved Revatio (sildenafil 20 mg, taken three times daily) for WHO Group I pulmonary arterial hypertension to improve exercise ability and delay clinical worsening. It remains the only PDE5 inhibitor approved in both tablet and intravenous formulations for PAH — the IV option matters for patients too ill to swallow pills or those transitioning in a hospital setting. Four years later, Adcirca (tadalafil 40 mg once daily) joined the approved list, offering a simpler dosing schedule. Notably, a third ED drug, vardenafil (Levitra), is not FDA-approved for PAH, so patients and caregivers should not assume all drugs in this class are interchangeable. The distinction between the brand names matters practically. Revatio and Adcirca are dosed differently from their ED counterparts (Viagra and Cialis), carry different labeling, and may be covered differently by insurance. A prescription for “sildenafil 20 mg” for PAH is not the same as a prescription for “sildenafil 100 mg” for erectile dysfunction, even though the active ingredient is identical.
Why Pulmonary Arterial Hypertension Matters for Brain Health
Pulmonary arterial hypertension does not just damage the lungs and heart — it compromises oxygen delivery to every organ, including the brain. When the right ventricle struggles to push blood through narrowed pulmonary arteries, less oxygenated blood returns to the left side of the heart for distribution to the body. The brain is exquisitely sensitive to drops in oxygen supply. Chronic hypoxia has been linked to cognitive impairment, difficulty with attention and executive function, and in some studies, accelerated neurodegeneration. For families already managing a dementia diagnosis, an overlapping PAH diagnosis complicates the picture considerably.
Cognitive symptoms from oxygen deprivation can mimic or worsen Alzheimer’s-related decline, making it harder for clinicians to determine which condition is driving which symptom. Treating the PAH — improving pulmonary blood flow and oxygen saturation — may stabilize or even modestly improve some cognitive deficits that were being driven by poor perfusion rather than by neurodegenerative disease itself. However, this does not mean PDE5 inhibitors are cognitive enhancers or dementia treatments. Some preliminary research has explored whether sildenafil might have neuroprotective properties through improved cerebral blood flow, but these studies are early-stage and far from conclusive. Patients and caregivers should be wary of extrapolating PAH treatment benefits into claims about Alzheimer’s prevention or reversal. The drugs treat a specific vascular condition; any cognitive benefit is secondary to improved oxygen delivery, not a direct effect on amyloid plaques or tau tangles.
How Revatio and Adcirca Differ in Practice
On paper, both sildenafil (Revatio) and tadalafil (Adcirca) do the same thing: block PDE5 to relax pulmonary blood vessels. In practice, the differences matter to patients and their caregivers. Revatio is dosed at 20 mg three times a day, roughly every eight hours. That means managing a medication schedule three times daily — a genuine burden for patients with cognitive impairment or those who depend on caregivers who are already juggling multiple drug regimens. Adcirca, at 40 mg once daily, simplifies this considerably. For someone with early-stage dementia living independently, the difference between remembering one pill and three can be the difference between consistent treatment and dangerous gaps. Side effect profiles overlap but are not identical.
Common side effects of Adcirca include headache, muscle pain, nasopharyngitis, flushing, respiratory tract infection, back pain, and nausea. Sildenafil carries a similar list. Both drugs interact dangerously with nitrates — a critical concern for older adults who may also have coronary artery disease and use nitroglycerin. Any patient taking a PDE5 inhibitor for PAH must have this flagged prominently in their medical record, because administering nitrates on top of these drugs can cause life-threatening drops in blood pressure. Cost is another real-world differentiator. Brand-name Revatio retails at roughly $665, but generic sildenafil 20 mg tablets are widely available and can cost as little as $4 to $13 through discount programs or coupons. Generic tadalafil is also available, though pricing varies. For families managing the already steep financial burden of dementia care, the availability of affordable generics for PAH treatment is a meaningful consideration.
Understanding PAH Diagnosis and Who Is Most at Risk
Pulmonary arterial hypertension is not a common disease, but it is not as rare as many people assume. Global estimates put prevalence at about 192,000 cases in 2021, with an age-standardized rate of 2.28 per 100,000 people. Women are disproportionately affected, comprising about 62 percent of cases (roughly 119,000 women versus 73,100 men). The reasons for this sex disparity are not fully understood, though hormonal factors and autoimmune conditions that are more common in women — such as scleroderma, which can trigger PAH — likely play a role. For caregivers and families in the dementia space, the age overlap is worth noting.
PAH can affect younger adults, but it also shows up in older populations where it may be dismissed as simple deconditioning or attributed entirely to aging. A person with dementia who becomes increasingly breathless with minimal activity, develops swelling in the legs, or experiences fainting spells deserves a workup that includes echocardiography and possibly right heart catheterization — not just an assumption that they are “slowing down.” Adcirca’s FDA indication specifically includes PAH associated with scleroderma and congenital heart disease, covering idiopathic, familial, and connective tissue disease-related forms. The tradeoff in pursuing a diagnosis is that right heart catheterization — the gold standard for confirming PAH — is invasive. For a patient with advanced dementia, the risks and distress of the procedure must be weighed against the potential benefit of treatment. There is no easy formula for this decision, and it should involve honest conversation among the care team, the patient (if capable of participating), and the family.
Survival Rates and the Limits of Treatment
Modern PAH treatments, including PDE5 inhibitors, have genuinely transformed outcomes. Data from the REVEAL Registry show survival rates of 91 percent at one year, 85 percent at three years, 68 percent at five years, and 49 percent at seven years from diagnosis. Compare that to historical data spanning 1980 to 2021, where one-year survival ranged from as low as 67 percent to as high as 99 percent depending on the era and treatment availability. The trajectory is clearly improving, and PDE5 inhibitors are part of that story, though they are usually used alongside other drug classes like endothelin receptor antagonists and prostacyclin analogs. But these numbers also tell a harder truth: even with treatment, nearly a third of PAH patients do not survive to five years, and roughly half do not reach seven. PAH remains a serious, progressive disease.
PDE5 inhibitors can improve exercise capacity and delay worsening, but they do not cure the underlying vascular remodeling. Globally, about 22,000 deaths were attributed to PAH in 2021. For older patients who also have dementia, the compounding effect of two progressive conditions demands realistic goal-setting. Treatment may focus more on comfort and functional maintenance than on aggressive disease modification. Families should also understand that “improvement in exercise ability” — the primary endpoint in PAH drug trials — is measured by the six-minute walk test. While clinically validated, this metric may not capture what matters most to a dementia patient or their family, such as the ability to participate in daily activities, maintain alertness, or avoid hospitalization.
Drug Interactions and Safety Concerns for Older Adults
Older adults with PAH and cognitive decline are often on multiple medications — cholinesterase inhibitors for dementia, antihypertensives, anticoagulants, and possibly antidepressants or antipsychotics. PDE5 inhibitors add another layer of interaction risk. The most dangerous interaction is with nitrates, as mentioned, but alpha-blockers can also cause additive blood pressure drops.
Certain antifungal and antibiotic medications that inhibit the CYP3A4 enzyme pathway can increase sildenafil and tadalafil levels in the blood, raising the risk of side effects. For a patient who cannot reliably report symptoms like dizziness, visual changes, or sudden hearing loss — all recognized adverse effects of PDE5 inhibitors — caregivers must be especially vigilant. A fall caused by orthostatic hypotension in an older person with PAH and dementia can cascade into a hip fracture, hospitalization, delirium, and rapid cognitive decline. The medication may be entirely appropriate, but the monitoring around it needs to be tighter than average.
Research Directions and the Brain-Lung Connection
The intersection of PDE5 inhibition and brain health is an active area of research, though one that requires cautious interpretation. Several observational studies have suggested that sildenafil users may have lower rates of Alzheimer’s disease, but these findings are confounded by the fact that people healthy enough to be taking ED drugs are generally healthier overall. Randomized controlled trials are needed before any causal claims can be made, and none have yet proven that PDE5 inhibitors prevent or treat dementia. What is more firmly established is that vascular health and brain health are deeply connected.
Anything that improves cardiovascular function — whether through medication, exercise, or dietary changes — tends to support better cognitive outcomes over time. For patients with PAH, treating the pulmonary vascular disease is not just about the lungs or the heart. It is about maintaining adequate perfusion to a brain that may already be under siege from neurodegeneration. That broader perspective — treating the whole patient rather than isolated organs — is where the most meaningful progress in both PAH and dementia care is likely to come.
Conclusion
Sildenafil (Revatio) and tadalafil (Adcirca) represent a remarkable chapter in drug repurposing, moving from erectile dysfunction treatment to life-extending therapy for pulmonary arterial hypertension. For families navigating dementia care, understanding these medications matters because PAH directly affects oxygen delivery to the brain, and untreated pulmonary hypertension can accelerate cognitive decline that might otherwise be manageable. The practical differences between the two drugs — three-times-daily dosing versus once daily, IV availability versus oral only, cost variations between brand and generic — are decisions that should be made with the full care team. The bigger takeaway is that cardiovascular and brain health are not separate conversations.
A breathless, fatigued older adult with dementia may have more going on than the dementia alone, and a proper workup for PAH could lead to treatment that meaningfully improves quality of life. At the same time, realistic expectations are essential. These drugs improve exercise capacity and delay progression; they do not reverse either PAH or dementia. The goal is to preserve function, reduce suffering, and give patients and families more good days — which, in the end, is what most of medicine is really about.
Frequently Asked Questions
Can I take Viagra instead of Revatio for pulmonary hypertension?
Sildenafil is the active ingredient in both, but dosing differs significantly. Revatio is prescribed at 20 mg three times daily for PAH, while Viagra is typically 25–100 mg as needed for ED. Your doctor must determine the correct formulation and dose. Do not substitute one for the other without medical guidance.
Does tadalafil (Adcirca) work better than sildenafil (Revatio) for PAH?
Head-to-head trials comparing the two are limited. Both improve exercise capacity in PAH patients. Adcirca offers the convenience of once-daily dosing, which can improve adherence, while Revatio is the only option available as an IV formulation for hospitalized patients. The choice often depends on individual patient needs, side effect tolerance, and cost considerations.
Could sildenafil or tadalafil help prevent Alzheimer’s disease?
Some observational studies have found associations between PDE5 inhibitor use and lower dementia risk, but correlation does not equal causation. People taking these drugs may simply be healthier overall. No randomized controlled trial has proven that these medications prevent or treat Alzheimer’s. Do not take them for this purpose without evidence from rigorous clinical trials.
Is pulmonary hypertension the same as regular high blood pressure?
No. Systemic hypertension (the common kind) involves elevated pressure in the arteries throughout the body. Pulmonary arterial hypertension specifically affects the blood vessels in the lungs and strains the right side of the heart. They are different conditions with different treatments, though a person can have both.
Are generic versions of these PAH drugs available?
Yes. Generic sildenafil 20 mg tablets are widely available and can cost as little as $4 to $13 with coupons or discount programs, compared to approximately $665 for brand-name Revatio. Generic tadalafil is also available. Ask your pharmacist about generic options and discount programs.
Why are women more likely to develop PAH than men?
About 62 percent of PAH cases occur in women. The exact reasons are not fully understood, but hormonal factors and the higher prevalence of autoimmune conditions like scleroderma in women — which can trigger PAH — are thought to contribute. Research into sex-specific mechanisms is ongoing.
